Bladder cancer drug shows promise in maintenance therapy study

NCT ID NCT05366725

Completed Disease control Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 25 times

Summary

This study looked at how safe and effective avelumab is as a maintenance treatment for adults with advanced bladder cancer that hasn't gotten worse after initial chemotherapy. Over 100 participants received avelumab in real-world settings and were followed for about 4 years. The goal was to see how long patients lived and describe their experiences with the drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
Churchill Hospital

Oxford, OX3 7LE, United Kingdom
Clatterbridge Hospital

Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Guy's and St Thomas' Hospital

London, SE1 9RT, United Kingdom
Lister Hospital

Stevenage, SG1 4AB, United Kingdom
Royal Preston Hospital

Preston, PR2 9HT, United Kingdom
Royal Surrey County Hospital

Guildford, GU2 7XX, United Kingdom
The Christie NHS Foundation Trust

Manchester, M20 4BX, United Kingdom
University College London Hospital

London, NW1 2PG, United Kingdom
University Hospitals Bristol

Bristol, BS1 3NU, United Kingdom

Conditions

Explore the condition pages connected to this study.

UROTHELIAL CANCER